09:34 AM EST - Marvel Biosciences Corp : Announces, along with its wholly owned subsidiary Marvel Biotechnology Inc., that it has initiated its 7-day dose-ranging, toxicology study, using rats, for its lead molecule MB-204. This is a vital step in preparation to initiate FDA Phase I human clinical trials. "This is the final milestone experiment we need to execute in order to identify the optimal doses for our upcoming 4-week GLP rat study, which in combination with our dog studies, will allow us to start human clinical testing of MB-204," said Dr. Mark Williams, Chief Science Officer. "We are commencing the dog dose ranging study shortly and will update the market on our progress shortly thereafter." Marvel Biosciences Corp
shares V.MRVL are trading unchanged at $0.14.
